Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6RI45
UPID:
BRWD3_HUMAN
Alternative names:
-
Alternative UPACC:
Q6RI45; C9IZ39; C9J3F3; Q2T9J6; Q5JRN1; Q6RI37; Q6RI42; Q6RI44; Q8N916
Background:
Bromodomain and WD repeat-containing protein 3, identified by the accession number Q6RI45, is pivotal in regulating cell morphology and cytoskeletal organization. It is essential for maintaining cell shape, indicating its critical role in cellular structure and function.
Therapeutic significance:
The protein is linked to Intellectual developmental disorder, X-linked 93, characterized by intellectual deficiency and, in some cases, macrocephaly. Understanding the role of Bromodomain and WD repeat-containing protein 3 could open doors to potential therapeutic strategies for this genetic disorder.